(OE) Prot #JZP385-202: A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Severe Residual Tremor in Participants

Project: Research project

Project Details

Effective start/end date2/2/232/2/26


  • ICON Clinical Research, LLC (Prot #JZP385-202 Amnd 1 // Prot #JZP385-202 Amnd 1)
  • Cavion, Inc. (Prot #JZP385-202 Amnd 1 // Prot #JZP385-202 Amnd 1)